Day: December 17, 2021

December 17, 2021 SBM Offshore is pleased to announce that it has secured a US$620 million bridge loan facility for the financing of the construction of FPSO Alexandre de Gusmão. The FPSO Alexandre de Gusmão will be deployed at the Mero field in the Santos Basin offshore Brazil. Mero is a project under Libra Consortium responsibility, in which Petrobras is the operator with 40 percent and with the following partners: Shell Brasil with 20 percent, TotalEnergies with 20 percent, CNODC and CNOOC Limited with 10 percent each, together with Pré-sal Petróleo S.A. (PPSA) as manager of this contract. The facility was secured by the special purpose company which will own FPSO Alexandre de Gusmão. Currently, SBM Offshore is the sole owner of this special purpose company. Discussions around the divestment of 45% of the equity ownership to partners...

Business combination with CM Life Sciences III results in approximately $1.3 billion in cash proceeds Combined company to trade on Nasdaq Global Market under ticker “EQRX”NEW YORK and CAMBRIDGE, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) — CM Life Sciences III (Nasdaq: CMLT, CMLTW, CMLTU), a life science-focused special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, and EQRx, Inc., a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced the completion of their business combination. The business combination was approved by CM Life Sciences III’s stockholders at its special meeting held on December 16, 2021. EQRx, Inc., the resulting combined company, and its common stock...

Continued Strength in E-Commerce Business Segment has Driven Revenue Growth  New York, NY, Dec. 17, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today announced that it will report record Quarterly Net Revenue, for its current operating Quarter – 3rd Fiscal Quarter 2022 (Period: October 1 – December 31, 2021).   Continued strength in the Company’s highest margin E-Commerce business segment has driven revenue growth.  This will be the 2nd consecutive Quarter in which the Company reports record Net Revenue.   The Company is working diligently on a number of potentially important catalysts.  Moving forward, the Company is confident in both its business prospects as well as its ability to execute. ABOUT TAURIGA...

WAKE FOREST, N.C., Dec. 17, 2021 (GLOBE NEWSWIRE) — Wake Forest Bancshares, Inc., (OTC: WAKE) parent company of Wake Forest Federal Savings and Loan Association, announced today that the Company reported earnings of $1,235,550 or $1.13 per share for its fiscal year ended September 30, 2021. The Company’s earnings for the prior fiscal year were $1,170,850 or $1.06 per share. Earnings for the current quarter were reported at $325,400 or $0.30 per share versus $268,550 or $0.24 per share for the quarter ended September 30, 2020. Renee H. Shaw, President and Chief Executive Officer, stated that the Company’s earnings were reflective of improving conditions associated with the re-opening of our economies from COVID 19 pandemic restrictions. The Company’s fiscal year results exceeded expectations and budgetary amounts established at...

Press release Outside trading hours – Regulated information* Brussels, 17 December 2021, 18h Results of the capital increase of KBC Group NV for the employees and effects on the transparency obligations The traditional annual capital increase reserved for the employees of KBC Group NV and some of its Belgian subsidiaries had, dd. 17 December 2021, the following effects on the share capital and the amount of shares/voting rights of KBC Group NV. – The share capital increased by 663 509.34 EUR to 1 459 535 533.42 EUR. – The total number of shares increased by 189 034 to 416 883 592 shares. The total number of voting rights also increased by 189 034 to 416 883 592. The most recent information on the capital and the number of shares of KBC Group NV can be consulted on www.kbc.com.   Transparency legislation aims to create transparency...

Talenom Plc, Stock exchange release 17 December 2021 at 19:00 EET Talenom Plc: Disclosure under chapter 9, section 10 of the securities market act (Allianz SE) Talenom Plc has received an announcement from Allianz SE on 17 December 2021. According to the announcement, the total number of Talenom shares owned by Allianz Vie S.A. increased above 5% of Talenom Plc’s total number of shares as a result of share transactions concluded on 17 December 2021. Total position of Allianz SE according to the notification:  % of shares and voting rights % of shares and voting rights through financial instruments Total of both in % Total number of shares and voting rights of issuerResulting situation on the date on which threshold was crossed or reached 5.02%   5.02% 43,790,252Notified details of the resulting situation on the date on which the...

FORESIGHT SOLAR & TECHNOLOGY VCT PLC LEI: 21380013CXOR8N6OD977 Financial HighlightsOrdinary Shares Total Net Assets as at 30 September 2021: £29.5m Ordinary Shares Net Asset Value per share as at 30 September 2021: 85.4p Foresight Williams Technology Shares Total Net Assets as at 30 September 2021: £12.8m Foresight Williams Technology Shares Net Asset Value per share as at 30 September 2021: 97.0pOrdinary Shares FundNet Asset Value per Ordinary Share at 30 September 2021 was 85.4p, representing an increase of almost 25% from the Net Asset Value per Ordinary Share of 68.9p as at 31 March 2021, following a rebound in market power prices forecast by the energy industry’s independent, external modelling agencies and strong performance in the underlying portfolio. At 30 September 2021, the fund held positions in 11 UK solar assets,...

Protocol Title: The Effect of CBD Gum on Nausea and Vomiting During Pregnancy New York, NY, Dec. 17, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today announced that it has formally submitted its Clinical Study Protocol (“Protocol”) to the Institutional Review Board (“IRB”).  The Company’s Protocol Title: “The Effect of CBD Gum on Nausea and Vomiting During Pregnancy”. The purpose of this Clinical Study is: to examine the Effects of Different Cannabidiol Doses on Reducing the Frequency and Severity of Nausea in Otherwise Healthy Pregnant Women with Excessive First Trimester Emesis and the Diagnosis of Hyperemesis Gravidarum. Hyperemesis Gravidarum is also known as: Morning Sickness On December 16, 2021 the...